drugset / Trial / NCT06769737

The Prolonging Effect of Dexmedetomidine on Spinal Anesthesia Through Different Routes if Administrations

NCT06769737 ↗

Phase 4 Not yet recruiting 75 enrolled King Abdulaziz Medical City
RandomizedParallel-groupSingle-blindBasic science

Summary

This prospective, double-blinded, randomized clinical trial aims to examine the effects of combining isobaric bupivacaine with dexmedetomidine administered intrathecally (IT), compared to the combination of isobaric bupivacaine administered intrathecally and dexmedetomidine administered intravenously (IV), on spinal anesthesia prolongation time in minutes, time of regression from Bromage score 3 to 0.

Timeline

Start
2025-03-01
Primary completion
2025-08-15
Completion
2025-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg Intrathecal
Subject Dexmedetomidine Other / unclassified 3 ug Intrathecal
Background Bupivacaine Other / unclassified 12 mg Intrathecal
Background Fentanyl Other / unclassified 20 ug Intrathecal

Indications

No indication recorded.